Chernykh T M, Malyugin D A, Khachaturov M V, Shefer A A, Zoloedov V I
Voronezh State Medical University named after N.N. Burdenko.
I.M. Sechenov First Moscow State Medical University.
Probl Endokrinol (Mosk). 2024 Feb 28;70(1):46-55. doi: 10.14341/probl13281.
Insulinoma is the most common hormonally active neuroendocrine tumor (NET) of the pancreas. In recent years, there has been a trend towards an increase in the incidence of NET especially insulinoma.
Summarizing and analyzing current data on various approaches to the treatment of insulinoma. Our review includes a comprehensive assessment of the advantages and disadvantages of currently available insulinoma treatment methods in comparison with past experience, as well as a review of promising methods that are not currently widely used.
Analysis of literature from such databases as scientific electronic library elibrary.ru, Pubmed, Google Scholar, MedLine, Scopus and Web of Science.
The most common treatment for insulinoma is surgery. For patients with high operative risk, alternative methods such as alcohol ablation, radiofrequency ablation, and tumor embolization may be used. Medications include the use of somatostatin analogues, diazoxide. The literature describes the potential benefit of the use of beta-blockers, phenytoin, glucagon, however, in clinical trials, these drugs have not demonstrated a significant effect. For the treatment of malignant and metastatically advanced insulinoma, targeted therapy (primarily Everolimus), chemotherapy, as well as embolization (including chemoembolization, radioembolization), radiofrequency ablation (RFA), microwave ablation and cryoablation, ultrasound ablation (HIFU), laser ablation, brachytherapy, irreversible electroporation are used.
The study of new drugs is an important task for scientists, among medications the most promising are new generations of somatostatin analogues, targeted drugs and chemotherapy drugs. The rare frequency of insulinoma makes it difficult to conduct randomized controlled trials and prospective studies. That is why physicians and scientists need to maintain close contacts with each other and take into account the experience of treating each patient with such disease, which will help develop effective treatment algorithms in the future.
胰岛素瘤是胰腺最常见的具有激素活性的神经内分泌肿瘤(NET)。近年来,NET尤其是胰岛素瘤的发病率有上升趋势。
总结和分析目前关于胰岛素瘤各种治疗方法的数据。我们的综述全面评估了当前可用的胰岛素瘤治疗方法与过去经验相比的优缺点,以及对目前未广泛使用的有前景的方法进行综述。
分析来自科学电子图书馆elibrary.ru、PubMed、谷歌学术、MedLine、Scopus和科学网等数据库的文献。
胰岛素瘤最常见的治疗方法是手术。对于手术风险高的患者,可使用酒精消融、射频消融和肿瘤栓塞等替代方法。药物包括使用生长抑素类似物、二氮嗪。文献描述了使用β受体阻滞剂、苯妥英、胰高血糖素的潜在益处,然而,在临床试验中,这些药物并未显示出显著效果。对于恶性和转移进展期胰岛素瘤的治疗,使用靶向治疗(主要是依维莫司)、化疗以及栓塞(包括化疗栓塞、放射性栓塞)、射频消融(RFA)、微波消融、冷冻消融、超声消融(HIFU)、激光消融、近距离放射治疗、不可逆电穿孔。
新药研究是科学家的一项重要任务,在药物中最有前景的是新一代生长抑素类似物、靶向药物和化疗药物。胰岛素瘤的罕见发病率使得进行随机对照试验和前瞻性研究变得困难。这就是为什么医生和科学家需要保持密切联系,并考虑治疗每例此类疾病患者的经验,这将有助于未来开发有效的治疗方案。